FDA Adverse Event Other Summary report: N

MITROFLOW AORTIC PERICARDIAL HEART VALVE

MDR report key: 1930345 · Received October 28, 2010

Report

Report Number
3004478276-2010-00009
Event Type
Other
Date Received
October 28, 2010
Date of Event
September 25, 2010
Report Date
October 28, 2010
Manufacturer
SORIN GROUP CANADA INC. MITROFLOW DIVISION
Product Code
LWR
PMA / PMN Number
P060038
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
MN, US
Reporter Occupation
NURSE

Narratives

Additional Manufacturer Narrative · 1

EVAL METHOD: A REVIEW OF THE DEVICE HISTORY RECORD WAS COMPLETED. RESULTS: THE MFG TRAVELLER AND THE STERILIZATION RECORDS FOR THE SUBJECT VALVE WERE PULLED AND REVIEWED BY QUALITY ASSURANCE AT SORIN GROUP (B)(4), MITROFLOW DIVISION. THE RESULTS CONFIRMED THAT THIS VALVE SATISFIED ALL MATERIAL, VISUAL, AND PERFORMANCE STANDARDS REQUIRED FOR A SIZE 25 MITROFLOW AORTIC PERICARDIAL HEART VALVE AT THE TIME OF MANUFACTURE AND RELEASE. NOTE: AS PART OF THE INVESTIGATION, THE REVIEW OF THE STERILIZATION RECORDS CONFIRMED THAT THE FOUR VALVES (S/NS (B)(4)) ASSOCIATED WITH THE ENDOCARDITIS CASES AT THIS FACILITY WERE NOT PROCESSED IN THE SAME STERILIZATION LOT.

Description of Event or Problem · 1

THE COMPANY WAS NOTIFIED THAT OUT OF 19 MITROFLOW VALVE IMPLANTS AT THE CUSTOMER'S FACILITY SINCE (B)(6) 2010, 4 PTS WERE DIAGNOSED WITH ENDOCARDITIS. FOR EACH CASE, STAPH EPIDERMIDIS WAS IDENTIFIED AS THE RESPONSIBLE ORGANISM. THE IMPLANTS OCCURRED IN (B)(6) 2010. ACCORDING TO THE INFO PROVIDED ON (B)(4), THE PT RECEIVING THE MITROFLOW VALVE (S/N (B)(4)) ON (B)(6) 2010, WAS DIAGNOSED WITH POSSIBLE ENDOCARDITIS AFTER BEING SEEN IN THE ED FOR SHAKING, CHILLS, AND FEVER ON (B)(6) 2010. BLOOD CULTURES WERE PERFORMED AND STAPHYLOCOCCUS EPIDERMIDIS WAS ISOLATED. A TEE WAS PERFORMED AND SHOWED NO VEGETATION AND THAT THE VALVE APPEARED OK.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 MITROFLOW AORTIC PERICARDIAL HEART VALVE TISSUE, HEART VALVE LWR SORIN GROUP CANADA INC. MITROFLOW DIVISION LXA NA

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention